Pliant Therapeutics has pumped the breaks on a midstage trial of its lead lung disease drug on the advice of its safety committee. The South San Francisco biotech has been evaluating 160-mg and ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

Pliant Therapeutics paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast after a safety board review. Get real-time earnings alerts before the market moves and access expert analysis ...

Pliant Therapeutics (NASDAQ:PLRX) stock plunged 61% in the wake of news that it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with idiopathic pulmonary fibrosis.

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company’s shares closed last Friday at $7.79. Leverage the ...

A committee of clinical trial monitors has advised Pliant Therapeutics to stop giving its experimental fibrosis drug to patients in a Phase 2 trial, seeding doubt about the therapy’s future.

Chrissy Teigen learned she is of Roma descent in an upcoming episode of "Finding Your Roots." In TODAY.com's exclusive clip of the Season 11 moment, the TV personality sat down with Henry Louis ...

Roma have expressed an interest in signing Casemiro on loan from Manchester United before the transfer deadline. It’s understood that the Italians are exploring the possibility of a deal for the ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board, the company has voluntarily paused ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Kosta Runjaic Formation: 3 - 5 - 2 Manager: Claudio Ranieri Formation ...

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...